New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:05 EDTBAYRY, ONXXBayer, Onyx announce Phase 3 DECISION trial of Nexavar meets primary endpoint
Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial of Nexavar tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. Adverse events were generally consistent with the known profile for Nexavar. Data from this study are expected to be presented at an upcoming medical meeting.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
11:40 EDTBAYRYBayer sees stock market flotation for MaterialScience unit by mid-2016 at latest
Subscribe for More Information
10:03 EDTBAYRYBayer announces capacity expansion at facilities producing weed control system
Subscribe for More Information
August 25, 2015
10:14 EDTBAYRYForward signs supplier agreement extension with Bayer Healthcare
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use